lilly tirzepatide approval https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound FDA approval for Zepbound (tirzepatide)

This is speculation based on the broader GLP-1 nasal delivery literature, not confirmed data for retatrutide specifically

In cases where participants were switched from DPP-4 inhibitor monotherapy, semaglutide was defined as the first-choice therapy

Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (step 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial

The precautionary principle would suggest we do our best to prevent aspiration events in these patients unless we have clear, high-quality evidence that patients taking GLP-1 RAs are not at increased risk of aspiration

For people taking GLP-1s like Zepbound, however, its especially important to take up resistance training, Dr

If its more than 12 hours since your scheduled injection time, skip that dose and continue from the following day